Journal Article

DKFZ-2026-00467

http://join2-wiki.gsi.de/foswiki/pub/Main/Artwork/join2_logo100x88.png Updates to Early Detection of Prostate Cancer: AUA/SUO Guideline (2026).

Lin, D. W. ; Carlsson, S.DKFZ* ; Filson, C. P. ; Kim, S. K. ; Kirkby, E. ; Konety, B. R. ; Purysko, A. S. ; Souter, L. H.

2026
Elsevier New York, NY [u.a.]

Abstract: The recommendations discussed on the early detection of prostate cancer provide a framework to facilitate clinical decision-making in the implementation of prostate cancer screening and follow-up.The Early Detection of Prostate Cancer Guideline was reviewed in 2025 and updated through the AUA amendment process. This process involved reviewing and integrating newly published literature into the previously established Guideline. The methodologist updated the original Guideline search strategy to systematically search Ovid MEDLINE and Embase for new evidence published between November 2022 and December 2024.The Early Detection of Prostate Cancer Amendment Panel updated evidence- and consensus-based Guideline statements to provide guidance on prostate cancer screening, imaging and biomarker use, initial and repeat biopsies, and biopsy technique.This update provides several new insights, including revised strength of evidence based on recently published literature on the use of MRI in biopsy-naïve patients and biopsy techniques, updates on available biomarkers, and revised recommendations for atypical small acinar proliferation. This Guideline will require future review and updates, as early detection and diagnostic strategies in this space continue to evolve.

Keyword(s): DRE ; MRI ; PSA ; biopsy ; early detection of cancer ; early detection of prostate cancer ; image-guided biopsy ; imaging ; male ; mass screening ; prostate cancer ; prostate cancer screening ; prostate/diagnostic imaging ; prostate/pathology ; prostatic neoplasms/diagnosis ; prostatic neoplasms/pathology ; risk calculator ; screening interval ; shared decision-making

Note: 2026 May;215(5):491-501

---

Contributing Institute(s):

1. C070 Klinische Epidemiologie der Krebsfrüherkennung (C070)

Research Program(s):

1. 313 - Krebsrisikofaktoren und Prävention (POF4-313) (POF4-313)

Appears in the scientific report 2026

---

Database coverage:
; BIOSIS Previews ; Biological Abstracts ; Clarivate Analytics Master Journal List ; Current Contents - Clinical Medicine ; Current Contents - Life Sciences ; Essential Science Indicators ; IF >= 5 ; JCR ; SCOPUS ; Science Citation Index Expanded ; Web of Science Core Collection

---